On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).